HomeNewsBusinessEconomyCoronavirus impact: COVID-19 tests the world's first pandemic bonds

Coronavirus impact: COVID-19 tests the world's first pandemic bonds

Due for redemption in July, the two pandemic bonds by World Bank worth $320 million have complicated payout triggers.

April 09, 2020 / 08:32 IST
Story continues below Advertisement
A worker sprays disinfectant as sanitization operations against Coronavirus are carried out in the museum hosted by the Maschio Angioino medieval castle, in Naples, Italy, Tuesday, March 10, 2020. (Alessandro Pone/LaPresse via AP)
A worker sprays disinfectant as sanitization operations against Coronavirus are carried out in the museum hosted by the Maschio Angioino medieval castle, in Naples, Italy, Tuesday, March 10, 2020. (Alessandro Pone/LaPresse via AP)

Even though the coronavirus pandemic has claimed more than 80,000 lives so far, the payout from the two pandemic bonds sponsored by the World Bank arm in July 2017 is yet to happen mainly due to the conditions outlined in the fine print.

The pandemic bonds, a novel funding mechanism set up by the lending arm of the World Bank, the International Bank for Reconstruction and Development (IBRD) in July 2017 and were expected to be redeemed in July 2020.

Story continues below Advertisement

These bonds were conceptualised in the wake of the Ebola epidemic in Africa in 2015 as a means of providing surge funding to developing countries to cope with the pandemic.

The $320 million bonds were part of a larger $425 million total amount of risk transferred to the market through bonds and derivatives. This involved a concurrent $105 million swap with six reinsurance counterparties too.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show